Marco Cavaleri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marco Cavaleri has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Buoninfante
Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands
3 shared publications - Arno C. Andeweg
Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications - Eric Pelfrene
European Medicines Agency
2 shared publications - Stephanie Buchholz
European Medicines Agency 1
2 shared publications Adam Hacker
Coalition for Epidemic Preparedness Innovations, Oslo, Norway
1 shared publicationAdam M Fimbo
Tanzania Medicines and Medical Devices Authority, Ubungo External, Dar es Salaam, Tanzania
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by ALTEX Edition in ALTEX
- Vol. 43 (4) , 559-581
A roadmap for modernizing vaccine safety assessment: Challenges and opportunities for new approach methodologies
Vaccines are administered to large populations of healthy individuals, including vulnerable groups, making an exceptionally rigorous safety profile a prerequisite for their approval and use. Nonclinical vaccine safety assessment has traditionally relied on standardized animal testing methodologies, which face increasing challenges: the ethical imperative to reduce animal use, the need for faster vaccine development, and the limitations of animal models in predicting human-specific immune responses. The advent of modern vaccine platforms such as mRNA technologies and viral-vector vaccines necessitates a re-evaluation of safety frameworks. This article explores emerging strategies to modernize vaccine safety assessment, integrating new approach methodologies (NAMs), including in vitro systems, artificial intelligence, and adverse outcome pathways (AOPs). Ethical refinements to animal husbandry practices, including group housing, humane endpoints, pain management and scaled blood sampling volumes, are also discussed to align with the principles of the 3Rs (replacement, reduction, refinement). The adoption of molecular and omics-based techniques, along with innovative validation strategies, offers opportunities to improve predictive accuracy and mechanistic insight. The article highlights a strategic framework for implementing NAMs across the three stages at which animals are still used – early screening, late nonclinical development, and batch release – while ensuring alignment with regulatory requirements. Implementation must be careful enough to ensure that the use of NAMs in the safety evaluation of vaccines maintains or exceeds current safety assessment standards. By addressing scientific, ethical, and regulatory challenges, NAMs have the potential to transform vaccine safety assessment, enhancing human relevance and accelerating innovation in vaccine development. Plain language summaryThis article examines the evolving landscape of vaccine safety assessment, focusing on opportunities to modernize testing approaches through new approach methodologies (NAMs). Drawing on recent discussions with stakeholders across industry, academia, and regulatory bodies, we outline key challenges and strategic pathways for implementing NAMs in vaccine development while maintaining robust safety standards. Special attention is given to emerging technologies, such as human-relevant test systems, artificial intelligence, and virtual control groups, to the replacement of animal-based potency, pyrogen and adventitious agent tests used for batch release, and to considerations for regulatory acceptance and implementation strategies.
- 13 October 2026
- Published by ALTEX Edition in ALTEX
- Vol. 43 (4) , 559-581
Open AccessA roadmap for modernizing vaccine safety assessment: Challenges and opportunities for new approach methodologies
Vaccines are administered to large populations of healthy individuals, including vulnerable groups, making an exceptionally rigorous safety profile a prerequisite for their approval and use. Nonclinical vaccine safety assessment has traditionally relied on standardized animal testing methodologies, which face increasing challenges: the ethical imperative to reduce animal use, the need for faster vaccine development, and the limitations of animal models in predicting human-specific immune responses. The advent of modern vaccine platforms such as mRNA technologies and viral-vector vaccines necessitates a re-evaluation of safety frameworks. This article explores emerging strategies to modernize vaccine safety assessment, integrating new approach methodologies (NAMs), including in vitro systems, artificial intelligence, and adverse outcome pathways (AOPs). Ethical refinements to animal husbandry practices, including group housing, humane endpoints, pain management and scaled blood sampling volumes, are also discussed to align with the principles of the 3Rs (replacement, reduction, refinement). The adoption of molecular and omics-based techniques, along with innovative validation strategies, offers opportunities to improve predictive accuracy and mechanistic insight. The article highlights a strategic framework for implementing NAMs across the three stages at which animals are still used – early screening, late nonclinical development, and batch release – while ensuring alignment with regulatory requirements. Implementation must be careful enough to ensure that the use of NAMs in the safety evaluation of vaccines maintains or exceeds current safety assessment standards. By addressing scientific, ethical, and regulatory challenges, NAMs have the potential to transform vaccine safety assessment, enhancing human relevance and accelerating innovation in vaccine development. Plain language summaryThis article examines the evolving landscape of vaccine safety assessment, focusing on opportunities to modernize testing approaches through new approach methodologies (NAMs). Drawing on recent discussions with stakeholders across industry, academia, and regulatory bodies, we outline key challenges and strategic pathways for implementing NAMs in vaccine development while maintaining robust safety standards. Special attention is given to emerging technologies, such as human-relevant test systems, artificial intelligence, and virtual control groups, to the replacement of animal-based potency, pyrogen and adventitious agent tests used for batch release, and to considerations for regulatory acceptance and implementation strategies.
- Open Access
- 1 September 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 69, 101844
Public trust and evidence: decisions on vaccines must be anchored in science
- 1 September 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 69, 101844
Open AccessPublic trust and evidence: decisions on vaccines must be anchored in science
- Open Access
- 30 April 2026
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 381 (1949)
Use of animal efficacy, pharmacokinetic/pharmacodynamic and first in human data for regulatory approval of treatment options against chemical, biological, radiological and nuclear threats
Chemical, biological, radiological and nuclear (CBRN) agents can pose a significant risk to public health. Concerningly, for many of the CBRN threats there are no treatment options available. Conducting pivotal randomized controlled trials (RCTs) usually required for regulatory approval of medicinal products may not be feasible for medical countermeasures (MCM) intended for the treatment of CBRN threats because of the low prevalence and case numbers and ethical concerns on conducting RCTs, considering the potential serious health outcomes associated with CBRN threats. This is concerning, as it hampers the development and availability of new treatments against CBRN threats, which are needed for preparedness to ensure appropriate response to an outbreak. This review outlines alternative, regulatory flexible approaches that were used for the approval under exceptional circumstances of therapeutic MCMs against biological threats in the European Union. Considerations on the requirements of using animal efficacy data as key evidence for inferring efficacy from animals to humans, on using animal pharmacokinetic/pharmacodynamic data including pharmacometric modelling and simulation approaches to predict the human dose and on generating safety data in healthy humans are discussed. Challenges and advantages of this approach are highlighted, including the lessons learned based on the examples of tecovirimat, zanamivir and obiltoxaximab. This article is part of the Theo Murphy meeting issue ‘Evaluating anti-infective drugs’.
- 30 April 2026
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 381 (1949)
Open AccessUse of animal efficacy, pharmacokinetic/pharmacodynamic and first in human data for regulatory approval of treatment options against chemical, biological, radiological and nuclear threats
Chemical, biological, radiological and nuclear (CBRN) agents can pose a significant risk to public health. Concerningly, for many of the CBRN threats there are no treatment options available. Conducting pivotal randomized controlled trials (RCTs) usually required for regulatory approval of medicinal products may not be feasible for medical countermeasures (MCM) intended for the treatment of CBRN threats because of the low prevalence and case numbers and ethical concerns on conducting RCTs, considering the potential serious health outcomes associated with CBRN threats. This is concerning, as it hampers the development and availability of new treatments against CBRN threats, which are needed for preparedness to ensure appropriate response to an outbreak. This review outlines alternative, regulatory flexible approaches that were used for the approval under exceptional circumstances of therapeutic MCMs against biological threats in the European Union. Considerations on the requirements of using animal efficacy data as key evidence for inferring efficacy from animals to humans, on using animal pharmacokinetic/pharmacodynamic data including pharmacometric modelling and simulation approaches to predict the human dose and on generating safety data in healthy humans are discussed. Challenges and advantages of this approach are highlighted, including the lessons learned based on the examples of tecovirimat, zanamivir and obiltoxaximab. This article is part of the Theo Murphy meeting issue ‘Evaluating anti-infective drugs’.
- Open Access
- 24 November 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 249
Reply to “Investigating a role for NSAIDs in the pathophysiology of vaccine-associated myocarditis”
Hoption Cann proposes that nonsteroidal anti-inflammatory drugs (NSAID)s could play an important role in the pathophysiology of vaccine-associated myocarditis and could also have a synergistic effect with COVID-19 vaccines, because NSAIDs are administered often as antipyretic medications. At this stage no hypothesis should be rejected a priori; however, we need to maintain rigor in the scientific evaluations so to advance research primarily towards the most plausible mechanisms.
- 24 November 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 249
Open AccessReply to “Investigating a role for NSAIDs in the pathophysiology of vaccine-associated myocarditis”
Hoption Cann proposes that nonsteroidal anti-inflammatory drugs (NSAID)s could play an important role in the pathophysiology of vaccine-associated myocarditis and could also have a synergistic effect with COVID-19 vaccines, because NSAIDs are administered often as antipyretic medications. At this stage no hypothesis should be rejected a priori; however, we need to maintain rigor in the scientific evaluations so to advance research primarily towards the most plausible mechanisms.
- Open Access
WHO Workshop Report: Regulatory Science to Inform Clinical Pathways for Shigella Vaccines Intended for Use in Children in Low- and Middle-Income Countries
Infectious diarrhea caused by Shigella remains a significant global health concern, and several vaccine candidates are approaching phase III clinical studies in the target population of young children in low- and middle-income countries. The World Health Organization (WHO) has published preferred product characteristics (PPCs) for Shigella vaccines to provide strategic guidance that aids in advancing product development and highlights policy considerations for use in LMIC settings where the vaccine is most needed. However, the selection of appropriate clinical endpoints was not clearly defined within the PPCs and remains an important issue for phase III study design. Previously, an expert panel identified areas of alignment and consensus on many clinical study design components while also recognizing that further discussions and data were required to solidify recommendations on key study design aspects. Therefore, WHO convened a diverse range of stakeholders, including manufacturers, regulators, and policymakers across national, regional, and global levels, with the aim of achieving consensus and soliciting inputs from the regulatory community surrounding vaccine phase III study design considerations. The intent of this report is to outline the key points from those discussions to inform the phase III design strategies and investment decisions of product developers and donors and to share recommendations for next steps.
Open AccessWHO Workshop Report: Regulatory Science to Inform Clinical Pathways for Shigella Vaccines Intended for Use in Children in Low- and Middle-Income Countries
Infectious diarrhea caused by Shigella remains a significant global health concern, and several vaccine candidates are approaching phase III clinical studies in the target population of young children in low- and middle-income countries. The World Health Organization (WHO) has published preferred product characteristics (PPCs) for Shigella vaccines to provide strategic guidance that aids in advancing product development and highlights policy considerations for use in LMIC settings where the vaccine is most needed. However, the selection of appropriate clinical endpoints was not clearly defined within the PPCs and remains an important issue for phase III study design. Previously, an expert panel identified areas of alignment and consensus on many clinical study design components while also recognizing that further discussions and data were required to solidify recommendations on key study design aspects. Therefore, WHO convened a diverse range of stakeholders, including manufacturers, regulators, and policymakers across national, regional, and global levels, with the aim of achieving consensus and soliciting inputs from the regulatory community surrounding vaccine phase III study design considerations. The intent of this report is to outline the key points from those discussions to inform the phase III design strategies and investment decisions of product developers and donors and to share recommendations for next steps.
- Open Access
- 27 March 2025
- Published by Elsevier in The Lancet Global Health
- Vol. 13 (4) , e769-e777
A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems
- 27 March 2025
- Published by Elsevier in The Lancet Global Health
- Vol. 13 (4) , e769-e777
Open AccessA roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems
- Open Access
- 31 August 2024
- Published by Springer Nature
- p. 129-146
6 Meeting Regulatory Criteria and Seeking Licensure: Medicines Development Before and During Public Health Emergencies
The Ebola outbreak of 2014 and the COVID-19 pandemic have underscored the importance of expedited preclinical and clinical product development to assure access to life-saving therapies during public health emergencies. Advances in manufacturing methods and the availability of platform technologies provide opportunities for streamlined product development by leveraging data derived from other products based on the same platform. Use of adaptive and seamless clinical trial designs, especially during the COVID-19 pandemic, led to more rapid progress through phases of clinical development and resulted in earlier availability of therapeutics and vaccines to billions of people. Regulatory agencies played a critical role in this process as they were tasked with an expedited assessment of preclinical, clinical, and manufacturing protocols and data to ensure product safety and effectiveness. At the same time, regulators had to balance benefits and risks in a rapidly evolving scenario, thus emphasizing the importance of transparent communication. Close collaboration between the global regulatory community, manufacturers, the scientific community, and global public health authorities was essential in this process. Lessons learned from these public health emergencies demonstrate that use of novel preclinical and clinical testing strategies, continued improvements in efficiency of product assessment, and further strengthening of global regulatory collaboration, using more convergence in standards and reliance in procedural aspects, are necessary to ensure an effective and timely response to future pandemics.
- 31 August 2024
- Published by Springer Nature
- p. 129-146
Open Access6 Meeting Regulatory Criteria and Seeking Licensure: Medicines Development Before and During Public Health Emergencies
The Ebola outbreak of 2014 and the COVID-19 pandemic have underscored the importance of expedited preclinical and clinical product development to assure access to life-saving therapies during public health emergencies. Advances in manufacturing methods and the availability of platform technologies provide opportunities for streamlined product development by leveraging data derived from other products based on the same platform. Use of adaptive and seamless clinical trial designs, especially during the COVID-19 pandemic, led to more rapid progress through phases of clinical development and resulted in earlier availability of therapeutics and vaccines to billions of people. Regulatory agencies played a critical role in this process as they were tasked with an expedited assessment of preclinical, clinical, and manufacturing protocols and data to ensure product safety and effectiveness. At the same time, regulators had to balance benefits and risks in a rapidly evolving scenario, thus emphasizing the importance of transparent communication. Close collaboration between the global regulatory community, manufacturers, the scientific community, and global public health authorities was essential in this process. Lessons learned from these public health emergencies demonstrate that use of novel preclinical and clinical testing strategies, continued improvements in efficiency of product assessment, and further strengthening of global regulatory collaboration, using more convergence in standards and reliance in procedural aspects, are necessary to ensure an effective and timely response to future pandemics.
- Top Cited PapersOpen Access
- 28 June 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-8
Myocarditis associated with COVID-19 vaccination
Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to several million people and the risk of myocarditis post COVID-19 vaccination has been characterised in great detail. At the present time the research data available are scarce and there is still no clear understanding of the biological mechanism/s responsible for this disease. This manuscript provides a concise overview of the epidemiology of myocarditis and the most prominent mechanistic insights in the pathophysiology of the disease. Most importantly it underscores the needed next steps in the research agenda required to characterize the pathophysiology of this disease post-COVID-19 vaccination. Finally, it shares our perspectives and considerations for public health.
- 28 June 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-8
Top Cited PapersOpen AccessMyocarditis associated with COVID-19 vaccination
Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to several million people and the risk of myocarditis post COVID-19 vaccination has been characterised in great detail. At the present time the research data available are scarce and there is still no clear understanding of the biological mechanism/s responsible for this disease. This manuscript provides a concise overview of the epidemiology of myocarditis and the most prominent mechanistic insights in the pathophysiology of the disease. Most importantly it underscores the needed next steps in the research agenda required to characterize the pathophysiology of this disease post-COVID-19 vaccination. Finally, it shares our perspectives and considerations for public health.
- 28 May 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (8) , 2109-2110
Generating clinical evidence for treatment and prevention options for long COVID
- 28 May 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (8) , 2109-2110
Generating clinical evidence for treatment and prevention options for long COVID
- Open Access
- 10 February 2024
- Published by Elsevier in Biologicals
- Vol. 85, 101745
Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023
- 10 February 2024
- Published by Elsevier in Biologicals
- Vol. 85, 101745
Open AccessFourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023